Sever P, Dahlof B, Poulter N, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen S, McInnes G, Mehlsen J, Nieminen M, O’Brien E, Ostergen J. Rationale, design, methods and baseline demographic data of participants in the Anglo-Scandinavian Cardiac Outcomes Trial. J Hypertension 2001;19:1139-1147
Sever P, Dahlof B, Poulter N, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen S, McInnes G, Mehlsen J, Nieminen M, O’Brien E, Ostergen J. Anglo-Scandinavian Cardiac Outcomes Trial : a brief history, rationale and outline protocol. J Human Hypertens 2001;15 (Suppl 1):S11-12
Stanton A, Fitzgerald D, Hughes A, Mayet J, O’Brien E, Poulter N, Sever P, Shields D, Thom S. An intensive phenotyping study to enable the future examination of genetic influences on hypertension associated cardiovascular disease. J Human Hypertens 2001;15 (Suppl 1):S13-18
O’Brien E, Gribben C, Stanton A, Atkins N, Lyons S. Left ventricular hypertrophy and silent ischemia: A pilot study to examine the relationship in hypertensive patients. J Human Hypertens 2001;15 (Suppl 1):S75-77
O’Neill H, O’Brien E, Stanton A, Hedditch K. The suitability of an automated blood pressure measuring device – the Omron HEM-705CP – in a large multicentre study: the ASCOT Study. J Human Hypertens 2001;15 (Suppl 1):S83-85
O’Brien E. Editorial Note. Anglo-Scandinavian Cardiac Outcomes Trial. ASCOT. Main Protocol Summary and Sub-Study Protocols. J Human Hypertens 2001;15 (Suppl 1)S1
Sever PS, Dahlöf B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O’Brien E, Östergren J, for the ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003;361:1149-1158. Published online April 2, 2003: http://image.thelancet.com/extras/03art3046web.pdf
Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O’Brien E, Ostergren J; ASCOT Investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial–Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Drugs. 2004;64 Suppl 2:43-60.
Sever PS, Poulter NR, Dahlöf B, Wedel H, Collins R, Beevers G, Caulfield M, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O’Brien E, Ostergren J for the ASCOT investigators. Reduction in Cardiovascular Events With Atorvastatin in 2532 patients with type 2 diabetes.ASCOT-LLA. Diabetes Care 2005;28:1151-1157.
Dahlöf B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O´Brien E, Östergren J for the ASCOT investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomized controlled trial. Lancet. www.thelancet.com Published online September 4, 2005 DOI:10.1016/S0140-6736(05)67185-1. Lancet 2005:366:895-906.
Poulter NR, Wedel H, Dahlöf B, Sever PS, Beevers DG, Caulfield M, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O´Brien E, Östergren J, Pocock S for the ASCOT nvestigators. Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA) Lancet. www.thelancet.com Published online September 4, 2005 DOI:10.1016/S0140-6736(05)67186-3. Lancet 2005:366:907-913.
Sever PS, Poulter NR, Dahlöf B,Wedel H for the Anglo-Scandinavian Cardiac Outcomes Trial Investigators. Different Time Course for Prevention of Coronary and Stroke Events by Atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial–Lipid-Lowering Arm (ASCOT-LLA). Am J Cardiol 2005;96[suppl]:39F–44F.
Lindgren P. Buxton M, Kahan T, Poulter NR, Dahloff B, Sever PS, Wedel H, Jonsson B on behalf of the ASCOT investigators. Cost-effectiveness of atorvastatin for the prevention of coronary and stroke events: an economic analysis of the Anglo-Scandinavian Cardiac Outcomes Trial—lipid-lowering arm (ASCOT-LLA). European Journal of Cardiovascular Prevention and Rehabilitation 2005:12:29–36
The CAFÉ Investigators for the ASCOT Investigators Differential Impact of Blood Pressure Lowering drugs on Central Aortic Pressure and Clinical Outcomes – Principal Results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 2006;113:1213-1225
Sever P, Dahloff B, Poulter N, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen S, Kristinsson A, McInnes G, Mehlsen J, Nieminem M, O’Brien E, Ostergren J on behalf of the ASCOT Steering Committee Members. Potential synergy between lipid-lowering and blood-pressure-lowering in the Anglo-Scandinavian Cardiac Outcomes Trial. Eur Heart J 2006:27:2982–2988
Chapman N, Dobson J, Wilson S, Dahlöf B, Sever PS, Wedel H, Poulter NR and on behalf of the Anglo-Scandinavian Cardiac Outcomes Trial Investigators. Effect of Spironolactone on Blood Pressure in Subjects With Resistant Hypertension. Hypertension 2007;49:839-845; originally published online Feb 19, 2007;DOI: 10.1161/01.HYP.0000259805.18468.8c
13. Lindgren EP, Buxton M, Kahan T, Poulter NR, Dahloff B, Sever PS, Wedel H. Jonsson B on behalf of the ASCOT trial investigators. Economic evaluation of ASCOT-BPLA: antihypertensive treatment with an amlodipine-based regimen is cost effective compared with an atenololbased regimen. Heart 2008;94;4; originally published online doi:10.1136/hrt.2007.127217
Sever PS, Poulter NR, Dahlof B, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes G, Mehlsen J, Nieminen MS, O’Bri ET, Ostergren J on behalf of the ASCOT Investigators. The Anglo-Scandinavian Cardiac Outcomes Trial: lipid lowering arm: extended observations 2 years after trial closure. Eur Heart J 2008; 29:499–508
Östergren J, Poulter NR, Sever PS, Dahlöf B, Wedel H. Beevers G,Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O’Brien E for the ASCOT investigators. The Anglo-Scandinavian Cardiac Outcomes Trial: blood pressure-lowering limb: effects in patients with type II diabetes. J Hypertens 2008;26:2103-2111
Dolan E, Stanton A, Caulfield M, Thom S, McInnes G, Collier D, Atkins N, Dicker P, O’Brien E on behalf of the ASCOT investigators. Ambulatory blood pressure monitoring predicts cardiovascular events in treated hypertensive patients – an Anglo-Scandinavian cardiac outcomes trial substudy. J Hypertens 2009, 27:876–885
Thom S, Stettler C,Stanton A, Witt N,Tapp R, Chaturvedi N, Allemann S, Mayet J, Sever P, Poulter N, O’Brien E, Hughes A. Differential Effects of Antihypertensive Treatment on the Retinal Microcirculation – An Anglo-Scandinavian Cardiac Outcomes Trial Substudy. Hypertension 2009;54:405-408
Williams B, Lacy PS,Cruickshank JK, Collier D, Hughes AD, Stanton A, Thom S, Thurston H, for the CAFE and ASCOT Investigators. Impact of Statin Therapy on Central Aortic Pressures and Hemodynamics. Principal Results of the Conduit Artery Function Evaluation–Lipid-Lowering Arm (CAFE-LLA) Study. Circulation. 2009;119:53-61
Stettler C, Witt N, Tapp RJ, Thom S, Allemann S, Tillin T, Stanton A, O’Brien E, Poulter N, Gallimore JR, Hughes AD, Chaturvedi N. Serum amyloid A, C-reactive protein, and retinal microvascular changes in hypertensive diabetic and nondiabetic individuals: an Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) substudy. Diabetes Care. 2009;32:1098-1100
Williams B, Lacy PS,Cruickshank JK, Collier D, Hughes AD, Stanton A, Thom S, Thurston H, for the CAFE and ASCOT Investigators. Impact of Statin Therapy on Central Aortic Pressures and Hemodynamics. Principal Results of the Conduit Artery Function Evaluation–Lipid-Lowering Arm (CAFE-LLA) Study. Circulation. 2009;119:53-61
